Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Trophos Announces Conclusion of MitoTarget Consortium

Published: Wednesday, August 01, 2012
Last Updated: Wednesday, August 01, 2012
Bookmark and Share
EU funded 3-year project spearheaded by orphan disease specialist Trophos reports results from neurodegenerative program to the European Commission.

Trophos SA has announced the conclusion of the pan-European MitoTarget Project, the EU funded orphan disease project, with submission of the final report to the EC.

The results obtained in this project included additional confirmation that mitochondrial dysfunction plays an important role in neuron death, and therefore the progression of neurodegenerative diseases.

The MitoTarget project contributed towards broader research required to discover which dysfunction/s is the leading cause of neurodegenerative diseases, key to finding effective drug targets in the future.

It also further confirmed that Trophos’ lead drug candidate olesoxime, currently in an ongoing pivotal trial for the orphan neuromuscular disease Spinal Muscular Atrophy (SMA), targets mitochondria.

Various changes in mitochondrial function, distribution or number were found in all experimental models of neurodegenerative diseases including Alzheimer's Disease, Huntington's Disease, Hereditary Spastic Paraplegia (HSP), Amyotrophic Lateral Sclerosis (ALS), and even general aging.

There were very promising results obtained in models of ALS, Huntington's Disease and Alzheimer's Disease.

Evidence produced by MitoTarget also proved mitochondrial targeted drugs should provide a part of the therapeutic strategy of neurodegenerative diseases.

Combination therapeutics will be essential to attack multiple aspects of the disease including both the causes and the symptoms.

Trophos and the consortium have already published many of their results and further publications are planned describing results of the basic research as well as the clinical trial in ALS to aid all parties involved in future research to work towards eradicating and curing diseases that include SMA, Alzheimer's Disease, Huntington’s Disease as well as ALS.

The three-year project was initiated in 2007 with the creation of the consortium, commencing the main part of the activity in 2009, and was funded by the EU.

Advocates included the British theoretical physicist, Stephen Hawking, CH, CBE, FRS, FRSA, and a patron of the Motor Neurone Disease Association.

Led by Trophos, the MitoTarget consortium consisted of 17 partners from four European countries (France, Germany, United Kingdom, and Belgium).

Fourteen of the partners as well as a centre in Spain participated in the clinical trial element of the project and five basic research groups focused on understanding the underlying mechanisms of neurodegenerative diseases.

“Trophos has been deeply honored to have led the MitoTarget Consortium, which has made significant discoveries that will help future research into neurological diseases,” said Rebecca Pruss, MitoTarget project principle investigator and Trophos’ chief scientific officer.

Pruss continued, “The research section of the project made considerable progress that will greatly contribute to, and benefit future efforts to find therapies for Alzheimer’s, Parkinson’s, Huntington’s diseases, ALS and other neurodegenerative diseases including Multiple Sclerosis.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Trophos Announces Results of Phase III Study of Olesoxime in ALS
Company continues its ongoing programs and financed until at least the end of 2013.
Wednesday, December 14, 2011
Scientific News
Developing a More Precise Seasonal Flu Vaccine
During the 2014-15 flu season, the poor match between the virus used to make the world’s vaccine stocks and the circulating seasonal virus yielded a vaccine that was less than 20 percent effective.
Fighting Cancer with Borrowed Immunity
A new step in cancer immunotherapy: researchers from the Netherlands Cancer Institute and University of Oslo/Oslo University Hospital show that even if one's own immune cells cannot recognize and fight their tumors, someone else's immune cells might.
Modified Microalgae Converts Sunlight into Valuable Medicine
A special type of microalgae can soon produce valuable chemicals such as cancer treatment drugs and much more just by harnessing energy from the sun.
Immune Cells Remember Their First Meal
Scientists at the University of Bristol have identified the trigger for immune cells' inflammatory response – a discovery that may pave the way for new treatments for many human diseases.
Paper Filter Can Remove Viruses from Water
A new paper filter can purify water from viruses, even the most difficult and contagious.
Large-scale HIV Vaccine Trial to Launch in South Africa
NIH-funded study will test safety, efficacy of vaccine regimen.
New HIV Vaccine Target Discovered
NIH-Led team have discovered a new vaccine target site on HIV.
Mimicking Evolution to Create Novel Proteins
A study by researchers in the Kuhlman lab offers a new route to design the 'cellular machines' needed to understand and battle diseases.
Antibody Therapy Opens Door to Potential New Treatment for HIV
Researchers at Rockefeller University show how a broadly neutralizing antibody could be used to help fight HIV.
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!